Vantage Consulting Group Inc Regeneron Pharmaceuticals, Inc. Transaction History

Vantage Consulting Group Inc

$68.1 Million
Q1 2024

A detailed history of Vantage Consulting Group Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Vantage Consulting Group Inc holds 244 shares of REGN stock, worth $252,352. This represents 0.34% of its overall portfolio holdings.

Number of Shares

244

Previous 277 11.91%

Holding current value

$252,352

Previous $243,000 3.7%

% of portfolio

0.34%

Previous 0.37%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$902.69 - $993.35 $29,788 - $32,780	-33 Reduced 11.91%	244 $234,000
Q4 2023 Feb 14, 2024	SELL	$775.18 - $881.7 $3,875 - $4,408	-5 Reduced 1.77%	277 $243,000
Q3 2023 Nov 14, 2023	SELL	$692.45 - $844.37 $17,311 - $21,109	-25 Reduced 8.14%	282 $232,000
Q2 2023 Aug 11, 2023	SELL	$700.03 - $830.35 $9,100 - $10,794	-13 Reduced 4.06%	307 $220,000
Q4 2022 Feb 13, 2023	SELL	$705.89 - $766.39 $27,529 - $29,889	-39 Reduced 10.86%	320 $230,000

Q3 2022 Nov 14, 2022	SELL	$573.97 - $724.32 $37,882 - $47,805	-66 Reduced 15.53%	359 $247,000
Q2 2022 Aug 09, 2022	BUY	$548.35 - $738.84 $36,191 - $48,763	66 Added 18.38%	425 $251,000
Q1 2022 May 16, 2022	SELL	$595.12 - $698.43 $18,448 - $21,651	-31 Reduced 7.95%	359 $251,000
Q4 2021 Feb 14, 2022	BUY	$543.48 - $670.97 $8,152 - $10,064	15 Added 4.0%	390 $246,000
Q3 2021 Nov 10, 2021	SELL	$574.03 - $680.96 $28,127 - $33,367	-49 Reduced 11.56%	375 $227,000
Q2 2021 Aug 11, 2021	BUY	$472.8 - $558.54 $200,467 - $236,820	424 New	424 $237,000
Q1 2021 May 14, 2021	SELL	$446.73 - $548.2 $68,349 - $83,874	-153 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$478.3 - $607.98 $73,179 - $93,020	153 New	153 $74,000

Others Institutions Holding REGN

# of Institutions

1,427

Shares Held

82.1M

Call Options Held

835K

Put Options Held

1.46M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $111B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vantage Consulting Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vantage Consulting Group Inc with notifications on news.

Account

Vantage Consulting Group Inc Regeneron Pharmaceuticals, Inc. Transaction History